Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-1956.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	16-Sep-2010
Complete List of Authors:	Planitzer, Christina; Baxter BioScience, Global Pathogen Safety Farcet, Maria; Baxter BioScience, Global Pathogen Safety Schiff, Richard; Baxter BioScience, Clinical Affairs Ochs, Hans; University of Washington and Seattle Children's Research Institute, Department of Pediatrics Kreil, Thomas; Baxter BioScience, Global Pathogen Safety
Keywords:	Intravenous Immunoglobulin, human - IVIG, Echoviruses, virus neutralization, antibody functionality, replacement therapy

SCHOLARONE™
Manuscripts

**Neutralization of different echovirus serotypes by individual lots of
intravenous immunoglobulin**

Christina B. Planitzer ¹, Maria R. Farcet ¹, Richard I. Schiff ², Hans D. Ochs ³, Thomas R. Kreil ¹

¹ Global Pathogen Safety, Baxter BioScience, Vienna, Austria

² Clinical Affairs, Baxter BioScience, West Lake Village, California

³ Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle,
Washington

Disclosure of potential conflict interest:

All work was performed at Global Pathogen Safety, Baxter BioScience, Vienna, Austria

With the exception of Hans D. Ochs, all authors are employees of Baxter BioScience.

Correspondence to: Thomas R. Kreil, PhD, Baxter BioScience, Benatzkygasse 2-6, 1221 Vienna, Austria.

e-mail: thomas_kreil@baxter.com; phone: + 43-1-20100-3860; fax: + 43-1-20100-3890

Running head: Echovirus neutralization by IVIG

Abstract

Replacement therapy using intravenous immunoglobulin (IVIG) preparations in people with antibody deficiencies is effective in preventing the majority of common bacterial and viral infections, yet echovirus break-through infections have occurred. Currently, only limited information on neutralization capacity variability of individual IVIG lots against the different echovirus serotypes is available.

Infectivity assays were established for the most prevalent echovirus serotypes (E 9, E 11, E 13 and E 30) circulating in the United States (US) and the European Union (EU). The echovirus serotype specific neutralization titers of 41 IVIG lots manufactured from either whole blood (Recovered) or collected by apheresis (Source) and from either the US or EU, were determined.

Significantly higher ($P < 0.0001$) neutralization titers against E 11 and E 30 were found in IVIG lots manufactured from US Source plasma compared to US Recovered plasma. Geographically, IVIG lots made from US plasma contained significantly ($P < 0.0001$) higher neutralization titers against E 9 and E 11 than lots manufactured from EU plasma, whereas lots made from EU plasma showed significantly higher neutralization of E 30.

To conclude, IVIG lots differ in their neutralizing antibody content against different echovirus serotypes, depending on plasma collection practices and geographic origin. Based on these results, an informed choice in selecting IVIG lots with the highest available neutralization titer against the specific echovirus serotype would seem to be beneficial during treatment of break-through infections.

3

Keywords

Intravenous immunoglobulin, human - IVIG; echoviruses; virus neutralization; antibody
functionality; replacement therapy

4

Introduction

Echoviruses belong to the human Enterovirus B group (family *Picornaviridae*) and 45 serotypes can be distinguished [CDC, 2006]. They are distributed worldwide and echovirus infections have been associated with diverse clinical outcomes, ranging from asymptomatic infection to minor febrile illness or persistent and severe, fatal conditions [Abzug, 2004]. More recently, an involvement of echovirus in the development of chronic diseases such as type 1 diabetes has been suggested [Viskari et al., 2004]. It has been estimated that echovirus is responsible for 10 to 15 million symptomatic infections in the US each year [CDC, 2006]. Clinically severe manifestations of echovirus infections are reported most frequently in two patient groups: (i) infants and young children (up to 4 years of age), accounting for approximately 60% of all echovirus infections [CDC, 2006], who are prone to develop severe echovirus infection with significant morbidity from sepsis, meningoencephalitis or myocarditis [Abzug et al., 1993; Abzug et al., 1995; Abzug, 2004; McKinney et al., 1987] and, (ii) people with antibody deficiency, particularly those with X-linked agammaglobulinemia, are at high risk to develop severe and / or chronic echovirus infections, particularly meningoencephalitis [McKinney, 1987].

While no specific therapy for echovirus infection is available, current clinical treatment regimen still include pleconaril [American Academy of Pediatrics, 2006; Abzug et al., 2004, Desmond et al., 2006]. Also, as antibodies are known to play an important role in the defense against enteroviral infections [Abzug et al., 1995], treatment of echovirus infection with intravenous immunoglobulin (IVIG) preparations has been suggested as beneficial [Abzug et al., 1995; Erlendsson et al., 1985; Galama et al., 2000; Johnston and Overall, 1989; Mease et al., 1981; Nagington, 1982; Nagington et al., 1983]. IVIG is a therapeutic preparation that contains the pooled antibodies from thousands of healthy plasma donors. Two different plasma

collection practices are utilized, where ‘Recovered’ plasma is collected from whole blood donations and ‘Source’ plasma is obtained from donors by apheresis. Previous work has shown that administration of IVIG with high echovirus antibody content improves clinical outcome [Abzug et al., 1995; Erlendsson et al., 1985; Galama et al., 1997; Galama et al., 2000; Johnston and Overall, 1989; McKinney et al., 1987; Mease et al., 1981; Nagington, 1982; Nagington et al., 1983] or protect those at risk of infection, especially during the echovirus season from June to October [CDC, 2006]. Although some of these studies have reported echovirus antibody titers for IVIG preparations and corresponding clinical efficacy, the specific results obtained are of limited value for current clinical use, since none of the products analyzed are available anymore [Abzug et al., 1995].

A number of echovirus serotypes have been associated with chronic enteroviral meningoencephalitis in agammaglobulinemic patients and are therefore of greatest concern for the Primary Immune Deficiency community (an estimated 250,000 children and adults in the US alone) [Boyle and Buckley, 2007]. The most frequent echovirus serotypes producing chronic enteroviral meningoencephalitis are: E 11 > E 9 > E 30 and > E 13 [McKinney, 1987]. In addition, E 13 has recently caused re-occurring severe disease in children with primary immune deficiency (R. Schiff, pers. communication). Echovirus serotypes show distinct epidemiologic characteristics and temporal patterns of circulation [Strikas et al., 1986]. Throughout the last decades E 9, E 11 and E 30 were reported most frequently in the general US [CDC, 2006] and EU [Ortner et al., 2009; RKI, 2010] populations, whereas E 13 has been circulating in the EU for some time but has only recently been associated with disease in the US [Mullins et al., 2004]. Previous efforts to link echovirus occurrence in the general population with echovirus antibody content of IVIG were not successful [Galama, 2000]. Other studies that investigated IVIG antibody specificities for different pathogens in IVIG lots suggested that antibody content varies

1 according to plasma donor age [Modrof et al., 2008], vaccination status [Audet et al., 2006;
2 Farcet et al., 2010] and virus epidemiology [Planitzer et al., 2007]. Because anecdotal evidence
3 suggests that understanding the echovirus antibody variation in IVIG lots could be of clinical
4 relevance for the treatment of persons with primary immune deficiency [Abzug et al., 1995;
5 Erlendsson et al., 1985; Galama et al., 2000; Johnston and Overall, 1989; Mease et al., 1981;
6 Nagington, 1982; Nagington et al., 1983], neutralization capacity of 41 IVIG lots against
7 echovirus serotypes E 9, E 11, E 30 and E 13 were determined. These serotypes are amongst the
8 most relevant for individuals with primary immune deficiency who are at increased risk of severe
9 systemic disease. This study presents the echovirus neutralization capacity of currently available
10 IVIG preparations and highlights important differences between IVIG lots manufactured from
11 plasma collected in different geographies and from different plasma donor population segments.

1
2
3 1 **Methods**

4
5 2 **Viruses and cells**

6
7
8 3 Virus isolates were obtained from the American Tissue Culture Collection (ATCC; E 9
9
10 4 strain ‘Hill’, ATCC VR-39; E 11 strain ‘Gregory’, ATCC VR-41; E 13 strain ‘Del Carmen’,
11
12 5 ATCC VR-43 and E 30 strain ‘Bastianni’, ATCC VR-322) and propagated and titrated on Vero
13
14 6 cells (European Collection of Cell Cultures, ECACC no. 84113001).
15
16
17
18
19

20
21 8 **IVIG preparations**

22
23
24 9 KIOVIG™ (Baxter AG, Vienna, Austria) and Gammagard Liquid™ (Baxter Healthcare Corp.,
25
26 10 Westlake Village, United States), are 10% liquid IVIG preparations produced by the same
27
28 11 manufacturing process. The licensed shelf life for these products is two years when stored at
29
30 12 2-8°C and the IgG subclass distribution is within the physiological range, i.e. IgG1 ≥ 56.9%,
31
32 13 IgG2 ≥ 26.6%, IgG3 ≥ 3.4% and IgG4 ≥ 1.7% [Teschner et al., 2007].
33
34
35
36 14 A total of 41 IVIG lots were analyzed in 2008. 23 lots were made from US plasma (12 lots from
37
38 15 Recovered and 11 lots from Source plasma) and 18 lots fractionated from EU plasma (2 lots from
39
40 16 Recovered and 16 lots from Source plasma). The dates of manufacture ranged from
41
42
43 17 December 2006 - November 2007 for US and from May 2006 – July 2007 for EU plasma derived
44
45
46 18 IVIG lots. The limited number of IVIG lots manufactured from EU Recovered plasma did not
47
48 19 allow a differential analysis between EU Source and Recovered plasma.
49
50
51
52
53
54
55
56
57
58
59
60

1 Titration of echovirus infectivity and determination of echovirus neutralization titers

2 Neutralization assays were performed at least in duplicate by two different operators and each
3 assay included internal controls for the verification of virus suspension infectivity. Equal volumes
4 containing 2,000 tissue culture infectious doses₅₀ (TCID₅₀) echovirus and serial twofold dilutions
5 of IVIG were mixed, incubated for one hour at room temperature and eightfold replicates per
6 dilution were transferred to a microtiter plate containing a Vero cell monolayer. After 7 days of
7 incubation at 37°C, cells were assessed for the presence of a cytopathic effect. The echovirus
8 neutralization titer, expressed as the test article dilution that resulted in 50% virus
9 neutralization (NT₅₀), was calculated from the number of negative wells and the initial sample
10 dilution according to the method of Reed and Muench [Reed and Muench, 1938]. Virus
11 concentrations were calculated according to the Poisson distribution and expressed as
12 log₁₀ TCID₅₀ per mL [Planitzer et al., 2009].

14 Statistical analysis

15 Statistical analysis was done using GraphPad Prism v5.0 software (San Diego, CA, USA).
16 Differences in IVIG antibody content were analyzed using the Student's t-test
17 (unpaired, two-tailed) and comparison of variance was done using the F-test.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Results

2 Echovirus neutralization titers of IVIG lots derived from Recovered versus Source plasma

3 collected in the US

4 There was a significant difference in neutralization titers for E 11 and E 30 (Fig. 1). IVIG lots

5 made from Source plasma had significantly higher ($P < 0.0001$) NT₅₀ values for E 11

6 (mean $\pm$ SEM, N; Source: 180 ± 7 , 11; Recovered: 135 ± 5 , 12) and E 30 (mean $\pm$ SEM, N;

7 Source: 611 ± 17 , 11; Recovered: 422 ± 17 , 12), as compared to lots derived from Recovered

8 plasma. The NT₅₀ values were approximately 3-fold higher for E 30 than for E 11 and the

9 difference between mean NT₅₀ values of Recovered versus Source plasma derived IVIG lots was

10 similar within the same echovirus serotype, i.e. Source NT₅₀ values were approx. 40% higher than

11 Recovered NT₅₀ values, for E 11 as well as for E 30. No significant difference in neutralization

12 titers for E 9 ($P = 0.48$) and E 13 ($P = 0.48$) was observed between Recovered and Source plasma

13 derived IVIG lots (Fig. 1).

14 Significant variation in NT₅₀ values obtained for IVIG against E 9 ($P = 0.02$) and E 13 ($P = 0.003$)

15 was seen.

16

17 Echovirus neutralization titers of IVIG lots derived from US or EU plasma

18 Significant differences in echovirus neutralization were observed for IVIG lots derived from US

19 or EU plasma, for E 9 ($P = 0.0002$), E 11 ($P < 0.0001$) and E 30 ($P = 0.0008$) (Fig. 2). IVIG lots

20 derived from US plasma had significantly higher NT₅₀ values for E 9 and E 11, whereas

21 EU plasma derived IVIG had significantly higher neutralization capacity for E 30. For E 13, no

22 difference ($P = 0.05$) in neutralization was observed between the IVIG lots tested (Fig. 2).

There was significant variability in echovirus NT₅₀ values for E 9 ($P = 0.01$), E 13 ($P = 0.01$) and E 30 ($P = 0.01$) within US plasma derived IVIG lots.

When the results were analyzed according to echovirus serotype and irrespective of plasma geographic origin and collection practices, the highest NT₅₀ values were obtained for E 30 (mean $\pm$ SEM, N; 559 ± 16 , 41), followed by E 9 (mean $\pm$ SEM, N; 285 ± 13 , 41), E 11 (mean $\pm$ SEM, N; 138 ± 5 , 41) and E 13 (mean $\pm$ SEM, N; 55 ± 3 , 41).

For Peer Review

Discussion

Even though IVIG lots are manufactured from the pooled plasma donations of several thousand donors, there is still a certain level of variation in antibody content between individual lots of IVIG [Lejtenyi and Mazer, 2008]. Previous studies have shown that antibody specificities in IVIG depend on the plasma donor population segment from which the plasma was collected [Modrof et al., 2008], their vaccination status [Audet et al., 2006; Farcet et al., 2010] or virus epidemiology [Planitzer et al., 2009]. These variations are linked to plasma collection practices, i.e. whole blood versus apheresis donations (Fig.1), as well as geographic origin of the plasma, i.e. US versus EU (Fig.2) [Galama et al., 1997].

To date, only four studies have evaluated the neutralizing antibody levels against the most common echovirus serotypes and reported highly variable levels in different IVIG products [Abzug et al., 1995; Galama et al., 1997; Galama et al., 2000; Mease et al., 1981]. This variability in reported antibody levels is, at least partially, explained by the use of different virus neutralization assay formats as well as different IVIG products, which are produced using different manufacturing procedures. Of note, these investigations were done prior to 2000 and included a limited number of IVIG lots no longer available, thus no information on echovirus antibody content in current IVIG preparations is available.

As it has been suggested that this information might be of vital importance to patients suffering from severe echovirus infections [Abzug et al., 1995; Erlendsson et al., 1985; Galama et al., 2000; Johnston and Overall, 1989; Mease et al., 1981; Nagington, 1982; Nagington et al., 1983], echovirus serotype specific antibody content in 41 IVIG lots, manufactured from plasma of different geographic and demographic origin, were determined.

The statistically higher E 11 and E 30 neutralization titers observed for Source plasma as compared to Recovered plasma-derived IVIG lots produced by the same manufacturing procedure during the same period of time were surprising, as earlier studies had revealed the exact opposite, i.e. higher measles virus [Audet et al., 2006] and parvovirus B19 (B19V) [Modrof et al., 2008] antibody titers in Recovered plasma-derived IVIG preparations. In both these cases, however, the generally older age of Recovered plasma donors (approx. two thirds of Source plasma donors are below 30 years of age, whereas the same proportion of Recovered plasma donors are older) has been shown to result in higher virus antibody titers. In the case of measles, higher titers are elicited after wild-type virus infection as opposed to exposure through a vaccine [Audet et al., 2006], and for B19V, higher prevalence of antibody-positive donors is found in advanced age groups [Modrof et al., 2008]. For echoviruses, however, exposure occurs uniformly by infection with wild-type virus as no vaccine exists, but the likelihood of infection is greater for infants and young children [CDC, 2006]. Of note, the overall level of circulation increased since 1975 for E 30 and since 1979 for E 11 [CDC, 2006] and thus titers can be expected to be highest for younger donors, and then declining during adolescence of donors towards the average age of Recovered plasma donors. However, with the limited information on the epidemiological occurrence of those viruses prior to 1970, the association of significantly higher titers with the younger age of Source plasma donors remains speculative.

As IVIG products reflect the immune status of a population subset, a certain degree of correlation should exist between echovirus incidence rates and echovirus neutralization capacity in individual lots of IVIG. A significantly greater E 9 antibody content in US plasma derived IVIG correlates well with an approximately 6-fold higher incidence of E 9 infections in the US [CDC, 2006] as compared to the EU [Ortner et al., 2009; RKI, 2010]. While the incidence rates reported for E 11 are similar for the US [CDC, 2006] and EU

[Ortner et al., 2009; RKI, 2010], results outlined in the presented study suggest that this echovirus serotype is more prevalent in the US, as evidenced by a significantly greater E 11 antibody content in US plasma derived IVIG. The relative infrequent occurrence of E 13 in the EU [RKI, 2010] and the US [CDC, 2006] is reflected by a low NT₅₀ observed in IVIG preparations from both geographic areas. The high incidence of E 30 reported from the EU [RKI, 2010] correlates well with the results obtained. However, the high antibody titers detected for E 30 in US plasma do not correlate well with E 30 incidence rates reported by the National Enterovirus Surveillance System (NESS), which indicate that E 30 is the third most prevalent echovirus serotype in the US, after E 9 and E 11 [CDC, 2006]. The E 30 antibody content detected in US IVIG was by far the highest for the echovirus serotypes included in this study, which may suggest that E 30 infections occur more frequently in the US than reported by the NESS, possibly reflecting underreporting due to the generally milder illness associated with this serotype [CDC, 2006], or even asymptomatic infections.

The presented results indicate that the surveyed echovirus serotypes occur at similar frequencies in both geographies, i.e. E 30 > E 9 > E 11 > E 13, and that, with the exception of E 30, the echovirus serotype specific antibody titers were always higher in US plasma derived IVIG. These results, in conjunction with the information gained from the analysis of Recovered versus Source plasma derived IVIG lots, are of importance to health care professionals who are treating patients with severe echovirus infection. By choosing an IVIG lot with the highest possible echovirus serotype specific antibody titer, it is possible to increase the amount of administered echovirus neutralizing antibodies by up to 3-fold, thereby maximizing the possible therapeutic benefit, as has previously been shown [Abzug et al., 1995; Erlendsson et al., 1985; Galama et al., 2000; Johnston and Overall, 1989; Mease et al., 1981; Nagington, 1982; Nagington et al., 1983]. Based on the findings of the presented surveillance study, a selection of

1
2
3 1 IVIG lots for substitution therapy during rare episodes of echovirus infection may be guided by
4
5 2 the recommendation given in Table I. As a certain level of variability in echovirus NT₅₀ titers was
6
7 3 already detected in this study, the echovirus serotype-specific neutralization capacity of IVIG lots
8
9 4 needs to be evaluated at regular intervals, in order to follow future trends in echovirus antibody
10
11 5 prevalence and to identify any shifts that could be relevant to substitution therapy.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

The neutralization capacity of individual lots of IVIG against the most prevalent echovirus serotypes varies up to threefold. These differences are linked to plasma collection practices, i.e. whole blood versus apheresis donations, as well as geographic origin of the plasma, i.e. US versus EU.

Despite IVIG substitution therapy, rare cases of infection by different echovirus serotypes occur in people with primary antibody deficiencies. Knowledge of the echovirus serotype neutralization titers of individual IVIG lots would enable targeted selection of higher titer lots against a specific echovirus serotype for substitution therapy during an infection episode.

Acknowledgements

We thank P. Noel Barrett, PhD for his long-term support and encouragement, and Don A. Baker, PhD for his unconditional support and strategic vision for the project. The contributions of the whole Global Pathogen Safety team, particularly Karin Berka, Elisabeth Pinter, Bettina York and Claudia Schwarr (virus propagation and cell culture) are gratefully acknowledged.

2 1
3
4
5
6 2 **References**
7
8

9
10 3 Abzug MJ, Levin MJ, Rotbart HA. 1993. Profile of enterovirus disease in the first two weeks of
11
12 4 life. *Pediatr Infect Dis J.* 12:820-4.
13
14
15 5 Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA. 1995. Neonatal enterovirus
16
17 6 infection: virology, serology, and effects of intravenous immune globulin. *Clin Infect Dis.*
18 7 20:1201-6.
19
20
21
22
23 8 Abzug MJ. 2004. Presentation, diagnosis, and management of enterovirus infections in neonates.
24 9 *Paediatr Drugs.* 6:1-10.
25
26
27
28
29 10 American Academy of Pediatrics. 2006. Red Book: 2006 Report of the Committee on Infectious
30
31 11 Diseases. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. *Enterovirus*
32 12 (Nonpoliovirus) Infections. Elk Grove Village, IL: American Academy of Pediatrics, p
33 13 284-85.
34
35
36
37
38
39 14 Audet S, Virata-Theimer ML, Beeler JA, Scott DE, Frazier DJ, Mikolajczyk MG, Eller N, Chen
40 15 FM, Yu MY. 2006. Measles-virus-neutralizing antibodies in intravenous
41 16 immunoglobulins. *J Infect Dis.* 194:781-9.
42
43
44
45
46
47 17 Boyle JM, Buckley RH. 2007. Population prevalence of diagnosed primary immunodeficiency
48 18 diseases in the United States. *J Clin Immunol.* 27:497-502.
49
50
51
52
53 19 Centers for Disease Control and Prevention. 2006. Enterovirus Surveillance - United States,
54 20 1970-2005. *Morb Mortal Wkly Rep.* 55: 1-20.
55
56
57
58
59
60

- 1 Desmond RA, Accortt NA, Talley L, Villano SA, Soong S-J, Whitley RJ. 2006. Enteroviral
2 meningitis: natural history and outcome of Pleconaril therapy. *Antimicrob Agents*
3 *Chemother.* 50:2409-14.
- 4 Erlendsson K, Swartz T, Dwyer JM. 1985. Successful reversal of echovirus encephalitis in X-
5 linked hypogammaglobulinemia by intraventricular administration of immunoglobulin.
6 *N Engl J Med.* 312:351-3.
- 7 Farcet MR, Planitzer CB, Stein O, Modrof J, Kreil TR. 2010. Hepatitis A virus antibodies in
8 immunoglobulin preparations. *J Allergy Clin Immunol.* 125:198-202.
- 9 Galama JM, Vogels MT, Jansen GH, Gielen M, Heessen FW. 1997. Antibodies against
10 enteroviruses in intravenous Ig preparations: great variation in titres and poor correlation
11 with the incidence of circulating serotypes. *J Med Virol.* 53:273-6.
- 12 Galama JM, Gielen M, Weemaes CM. 2000. Enterovirus antibody titers after IVIG replacement
13 in agammaglobulinemic children. *Clin Microbiol Infect.* 11:630-2
- 14 Johnston JM, Overall JC, Jr. 1989. Intravenous immunoglobulin in disseminated neonatal
15 echovirus 11 infection. *Pediatr Infect Dis J.* 8:254-6.
- 16 Lejtenyi D, Mazer B. 2008. Consistency of protective antibody levels across lots of intravenous
17 immunoglobulin preparations. *J Allergy Clin Immunol.* 121:254-5.
- 18 McKinney RE, Jr., Katz SL, Wilfert CM. 1987. Chronic enteroviral meningoencephalitis in
19 agammaglobulinemic patients. *Rev Infect Dis.* 9:334-56.

Mease PJ, Ochs HD, Wedgwood RJ. 1981. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. *N Engl J Med.* 304:1278-81.

Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, Aberham C, Gessner M, Kreil TR. 2008. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. *Transfusion.* 48:178-86.

Mullins JA, Khetsuriani N, Nix WA, Oberste MS, LaMonte A, Kilpatrick DR, Dunn J, Langer J, McMinn P, Huang QS, Grimwood K, Huang C, Pallansch MA. 2004. Emergence of echovirus type 13 as a prominent enterovirus. *Clin Infect Dis.* 38:70-7.

Nagington J. 1982. Echovirus 11 infection and prophylactic antiserum. *Lancet.* 1:446.

Nagington J, Gandy G, Walker J, Gray JJ. 1983. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. *Lancet.* 2:443-6.

Ortner B, Huang CW, Schmid D, Mutz I, Wewalka G, Allerberger F, Yang JY, Huemer HP. 2009. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. *J Med Virol.* 81:317-24.

Planitzer CB, Modrof J, Kreil TR. 2007. West Nile virus neutralization by US plasma-derived immunoglobulin products. *J Infect Dis.* 196:435-40.

Planitzer CB, Modrof J, Yu MY, Kreil TR. 2009. West Nile virus infection in plasma of blood and plasma donors, United States. *Emerg Infect Dis.* 15:1668-70.

- 1
2
3 1 Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;
4
5 2 27:493-7.
6
7
8 3 Robert Koch Institut. 2010. Bundesweite Enterovirus-Surveillance im Rahmen der
9
10 4 Polioeradikation: Ergebnisse aus den ersten vier Projektjahren. [online] Jan 2010
11
12 5 [accessed 25 May 2010]. Available at: [http://www.rki.de/cln_160/nn_494686/DE/](http://www.rki.de/cln_160/nn_494686/DE/Content/Infekt/EpidBull/Archiv/2010/01/Art__01.html)
13
14 6 Content/Infekt/EpidBull/Archiv/2010/01/Art__01.html.
15
16
17
18 7 Strikas RA, Anderson LJ, Parker RA. 1986. Temporal and geographic patterns of isolates of
19
20 8 nonpolio enterovirus in the United States, 1970-1983. J Infect Dis. 153:346-51.
21
22
23
24 9 Teschner W, Butterweck HA, Auer W, Muchitsch EM, Weber A, Liu SL, Wah PS, Schwarz HP.
25
26 10 2007. A new liquid, intravenous immunoglobulin product (IVIG 10%) highly purified by
27
28 11 a state-of-the-art process. Vox Sang. 92:42-55.
29
30
31
32 12 Viskari H, Ludvigsson J, Uibo R, Salur L, Marciulionyte D, Hermann R, Soltesz G,
33
34 13 Füchtenbusch M, Ziegler AG, Kondrashova A, Romanov A, Knip M, Hyöty H. 2004.
35
36 14 Relationship between the incidence of type 1 diabetes and enterovirus infections in
37
38 15 different European populations: results from the EPIVIR project. J Med Virol. 72:610-7.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21

1
2
3 1
4
5 2 Table I. Selection of IVIG lots for substitution therapy during echovirus infection episodes
6

EU - IVIG		US - IVIG	
		Source	Recovered
E 9		x	x [*]
E 11		x	
E 13	x	x [*]	x
E 30	x	x [*]	

21 3 *NT₅₀ values varied significantly within the group
22
23 4 EU: European Union, E: echovirus, NT₅₀: 50% virus neutralization; IVIG: Intravenous
24 5 immunoglobulin, US: United States
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Fig. 1. Echovirus neutralization titers 50% (NT₅₀) of individual IVIG lots manufactured from US plasma were determined and analyzed separately by plasma collection practice, i.e. Recovered (R) from whole blood donations or Source (S) collected by apheresis. Error bars indicate standard error of the means; asterisks indicate significant difference in mean titers ($P < 0.001$). N = number of IVIG lots tested.

Fig. 2. Echovirus neutralization titers 50% (NT₅₀) of individual IVIG lots manufactured from plasma collected in the European Union (EU) or the United States (US). Error bars indicate standard error of the means; asterisks indicate significant difference in mean titers ($P < 0.0001$). N = number of IVIG lots tested.

Fig. 1. Echovirus neutralization titers 50% (NT50) of individual IVIG lots manufactured from US plasma were determined and analyzed separately by plasma collection practice, i.e. Recovered (R) from whole blood donations or Source (S) collected by apheresis. Error bars indicate standard error of the means; asterisks indicate significant difference in mean titers ($P < 0.001$). N = number of IVIG lots tested.

Fig. 2. Echovirus neutralization titers 50% (NT50) of individual IVIG lots manufactured from plasma collected in the European Union (EU) or the United States (US). Error bars indicate standard error of the means; asterisks indicate significant difference in mean titers ($P < 0.0001$). N = number of IVIG lots tested.